Medical and Pharmaceutical Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days Developing drugs for the treatment of epilepsy, depression, obesity and other conditions is the company's forte Rowan DunneOctober 18, 2024
Health & Wellness Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research Partnership signals a milestone agreement for innovative treatment solutions Zartasha MushtaqJanuary 19, 2024
Psychedelics Afghanistan Veteran gets Health Canada approval for psilocybin treatment from Apex Labs Kelsi Sheren said that other treatment methods for her PTSD and depression were ineffective Rowan DunneSeptember 28, 2023
Psychedelics Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression Rowan DunneFebruary 1, 2023
Analysis Field Trip white paper makes strong health and business case for ketamine therapy With solid efficacy and low cost, the popular club drug could help curb the personal toll and multi-billion dollar cost of North America's battle... Natalia Buendia CalvilloFebruary 9, 2021